Literature DB >> 17851138

Turning off the G2 DNA damage checkpoint.

Teresa M Calonge1, Matthew J O'Connell.   

Abstract

In response to DNA damage, cells activate checkpoints to delay cell cycle progression and allow time for completion of DNA repair before commitment to S-phase or mitosis. During G2, many proteins collaborate to activate Chk1, an effector protein kinase that ensures the mitotic cyclin-dependent kinase remains in an inactive state. This checkpoint is ancient in origin and highly conserved from fission yeast to humans. Work from many groups has led to a detailed description of the spatiotemporal control of signaling events leading to Chk1 activation. However, to survive DNA damage in G2, the checkpoint must be inactivated to allow resumption of cell cycling and entry into mitosis. Though only beginning to be understood, here we review current data regarding checkpoint termination signals acting on Chk1 and its' upstream regulators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851138      PMCID: PMC2233850          DOI: 10.1016/j.dnarep.2007.07.017

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  48 in total

Review 1.  The G2-phase DNA-damage checkpoint.

Authors:  M J O'Connell; N C Walworth; A M Carr
Journal:  Trends Cell Biol       Date:  2000-07       Impact factor: 20.808

2.  Regulation of Saccharomyces Rad53 checkpoint kinase during adaptation from DNA damage-induced G2/M arrest.

Authors:  A Pellicioli; S E Lee; C Lucca; M Foiani; J E Haber
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 3.  Recycling the cell cycle: cyclins revisited.

Authors:  Andrew W Murray
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 4.  The p53 and Mdm2 families in cancer.

Authors:  Dan Michael; Moshe Oren
Journal:  Curr Opin Genet Dev       Date:  2002-02       Impact factor: 5.578

5.  PP2C phosphatases Ptc2 and Ptc3 are required for DNA checkpoint inactivation after a double-strand break.

Authors:  Christophe Leroy; Sang Eun Lee; Moreshwar B Vaze; Françoise Ochsenbein; Françoise Ochsenbien; Raphaël Guerois; James E Haber; Marie-Claude Marsolier-Kergoat
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

6.  PP1 control of M phase entry exerted through 14-3-3-regulated Cdc25 dephosphorylation.

Authors:  Seth S Margolis; Susan Walsh; Douglas C Weiser; Minoru Yoshida; Shirish Shenolikar; Sally Kornbluth
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

7.  Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors.

Authors:  Craig H Bassing; Heikyung Suh; David O Ferguson; Katrin F Chua; John Manis; Mark Eckersdorff; Megan Gleason; Rodrick Bronson; Charles Lee; Frederick W Alt
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

8.  Recovery from DNA damage checkpoint arrest by PP1-mediated inhibition of Chk1.

Authors:  Nicole R den Elzen; Matthew J O'Connell
Journal:  EMBO J       Date:  2004-02-05       Impact factor: 11.598

9.  Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways.

Authors:  Y Sanchez; B A Desany; W J Jones; Q Liu; B Wang; S J Elledge
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

Review 10.  Protein phosphatase 1--targeted in many directions.

Authors:  Patricia T W Cohen
Journal:  J Cell Sci       Date:  2002-01-15       Impact factor: 5.285

View more
  14 in total

1.  Proteolysis of Rad17 by Cdh1/APC regulates checkpoint termination and recovery from genotoxic stress.

Authors:  Liyong Zhang; Chi-Hoon Park; Jing Wu; Hyun Kim; Weijun Liu; Takeo Fujita; Manimalha Balasubramani; Emanuel M Schreiber; Xiao-Fan Wang; Yong Wan
Journal:  EMBO J       Date:  2010-04-27       Impact factor: 11.598

2.  MCL-1 localizes to sites of DNA damage and regulates DNA damage response.

Authors:  Sarwat Jamil; Cezar Stoica; Tillie-Louise Hackett; Vincent Duronio
Journal:  Cell Cycle       Date:  2010-07-11       Impact factor: 4.534

3.  Regulation of Chk1 by its C-terminal domain.

Authors:  Ana Kosoy; Matthew J O'Connell
Journal:  Mol Biol Cell       Date:  2008-08-20       Impact factor: 4.138

4.  Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.

Authors:  Hong Zhao; Frank Traganos; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2008-10-06       Impact factor: 4.534

5.  Regulatory motifs in Chk1.

Authors:  Michael L Caparelli; Matthew J O'Connell
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

6.  Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint.

Authors:  Yasunori Fukumoto; Mariko Morii; Takahito Miura; Sho Kubota; Kenichi Ishibashi; Takuya Honda; Aya Okamoto; Noritaka Yamaguchi; Atsushi Iwama; Yuji Nakayama; Naoto Yamaguchi
Journal:  J Biol Chem       Date:  2014-03-14       Impact factor: 5.157

7.  DNA damage during G2 phase does not affect cell cycle progression of the green alga Scenedesmus quadricauda.

Authors:  Monika Hlavová; Mária Čížková; Milada Vítová; Kateřina Bišová; Vilém Zachleder
Journal:  PLoS One       Date:  2011-05-16       Impact factor: 3.240

8.  Regulation of chk1.

Authors:  Claudia Tapia-Alveal; Teresa M Calonge; Matthew J O'Connell
Journal:  Cell Div       Date:  2009-04-29       Impact factor: 5.130

9.  The influence of sublethal blue light exposure on human RPE cells.

Authors:  Cora Roehlecke; Annette Schaller; Lilla Knels; Richard H W Funk
Journal:  Mol Vis       Date:  2009-09-21       Impact factor: 2.367

10.  CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Authors:  Mike I Walton; Paul D Eve; Angela Hayes; Melanie R Valenti; Alexis K De Haven Brandon; Gary Box; Albert Hallsworth; Elizabeth L Smith; Kathy J Boxall; Michael Lainchbury; Thomas P Matthews; Yann Jamin; Simon P Robinson; G Wynne Aherne; John C Reader; Louis Chesler; Florence I Raynaud; Suzanne A Eccles; Ian Collins; Michelle D Garrett
Journal:  Clin Cancer Res       Date:  2012-08-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.